> top > docs > PMC:7346000 > spans > 30240-31786 > annotations

PMC:7346000 / 30240-31786 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
789 343-349 Disease denotes Stress MESH:D000079225

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T239 586-589 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T240 1096-1099 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T241 1311-1314 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T242 1530-1533 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T231 196-199 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T232 916-919 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T233 995-997 http://www.ebi.ac.uk/efo/EFO_0000265 denotes Da
T234 1126-1127 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T235 1220-1222 http://www.ebi.ac.uk/efo/EFO_0000265 denotes Da

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T208 624-626 Chemical denotes NV http://purl.obolibrary.org/obo/CHEBI_73825

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T38 363-368 http://purl.obolibrary.org/obo/GO_0007568 denotes Aging

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T169 0-52 Sentence denotes M.H. received research funding by Gilead and Pfizer.
T170 53-190 Sentence denotes D.S.P. receives research support and/or serves on advisory boards for Amplyx, Cidara, Scynexis, N8 Medical, Merck, Regeneron, and Pfizer.
T171 191-692 Sentence denotes P.K. has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, and is an adivisor to, or received lecture honoraria from Akademie für Infektionsmedizin e.V., Astellas Pharma, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, NOXXON Pharma NV., and University Hospital, LMU Munich outside the submitted work.
T172 693-1546 Sentence denotes O.A.C. is supported by the German Federal Ministry of Research and Education; is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany’s Excellence Strategy (CECAD, EXC 2030 - 390661388); has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, MedPace, Melinta Therapeutics, MSD, Pfizer, and Scynexis; is a consultant to Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini Ricerche, Roche Diagnostics, MSD, Nabriva Therapeutics, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, and Vical; and received lecture honoraria from Astellas, Basilea, Gilead, Grupo Biotoscana, MSD, and Pfizer.